不同剂量米非司酮联合宫瘤清胶囊治疗子宫肌瘤的临床观察

Clinical observation of different dosages of mifepristone combined with Gongliuqing Capsule in the treatment of uterine fibroids

目的探讨不同剂量米非司酮联合宫瘤清胶囊治疗子宫肌瘤的效果。方法将2018年2月至2020年2月在廉江市人民医院诊治的104例子宫肌瘤患者随机分为观察组和对照组。观察组给予12.5 mg/d米非司酮联合宫瘤清胶囊治疗,对照组给予25 mg/d米非司酮联合宫瘤清胶囊治疗。比较两组的疗效、性激素水平、子宫体积、子宫肌瘤体积和不良反应。结果观察组和对照组的治疗总有效率分别为88.5%和94.2%。治疗3个月后与治疗前相比,两组的促卵泡生成激素(FSH)、促黄体生成素(LH)、雌二醇(E2)、孕酮(P)的浓度均明显低,子宫体积和子宫肌瘤体积均明显小(P<0.01),但疗效,FSH、LH、E2和P的浓度,子宫体积,子宫肌瘤体积在两组间的差异均无统计学意义(P>0.05)。观察组不良反应总发生率明显低于对照组(P<0.05)。结论12.5 mg/d或25 mg/d米非司酮联合宫瘤清胶囊治疗子宫肌瘤的疗效相当,但12.5 mg/d米非司酮联合宫瘤清胶囊方案的不良反应发生率更低。

Objective To explore the effect of different dosages of mifepristone combined with Gongliuqing Capsule on uterine fibroids.Methods A total of 104 patients with uterine fibroids treated in our hospital from February 2018 to February 2020 were randomly divided into the observation group and the control group.The observation group was given 12.5 mg/d mifepristone combined with Gongliuqing Capsule,while the control group was given 25 mg/d mifepristone combined with Gongliuqing Capsule.The curative effect,sex hormone level,the size of uterine,the size of uterine fibroids and adverse reactions of the two groups were compared.Results The total effective rates of the observation group and the control group were 88.5%and 94.2%,respectively.Three months after the treatment,the concentrations of FSH,LH,E2 and P in the two groups were significantly lower,and the uterine and the uterine fibroids were significantly smaller as compared with those before treatment(P<0.01).However,there was no significant difference in curative effect,concentration of FSH,LH,E2 and P,the size of uterine,the size of uterine fibroids between the two groups(P>0.05).The total incidence of adverse reactions in the observation group was significantly lower than that in the control group(P<0.05).Conclusion The efficacy of 12.5 mg/d mifepristone combined with Gongliuqing Capsule is equivalent to that of 25 mg/d mifepristone combined with Gongliuqing Capsule in the treatment of uterine fibroids,but the 12.5 mg/d mifepristone combined with Gongliuqing capsule has a lower adverse reaction rate.